Quantification and technique development to reduce ano-rectal toxicity in prostate radiotherapy.

Quantification and technique development to reduce ano-rectal toxicity in prostate radiotherapy. - Quantification and reduction of anorectal toxicity in prostate radiotherapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON33176

Enrollment

Registered

2009-07-06

Start date

2009-08-17

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer prostate carcinoma

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Biopsy proven prostate carcinoma. Localized prostate carcinoma (cT1-3N0M0) Written informed consent.

Exclusion criteria

Exclusion criteria: Previous treatment for this tumour, other than neo-adjuvant androgen suppression therapy. Distant metastases Contra-indications for radiotherapy (Morbus Crohn, ulcerative colitis, severe diverticulitis.

Design outcomes

Primary

Measure	Time frame
Subjective complaints, based on questionnaires. Anal pressures and rectal compliance. Amount and severity of telangiectasias to the rectal and sigmoid mucosa. In addition, the course of these parameters over 2 years and their correlation, and the correlation to the doses to the rectum and anal canal.	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results